Yes, generative AI is hyped. And yes, the technology has shortcomings. But the landscape is swiftly changing. Bloomberg Intelligence estimated that the GenAI market would grow from $40 billion in 2022 to $1.3 trillion by 2032. A recent study from Deloitte Consulting estimates that for a top 10 biopharma company with $65-75 billion in revenue,…
Pharma R&D ROI hits highest level since 2014
The pharmaceutical industry appears to have addressed a decade-long decline in R&D productivity, according to a recent analysis from Deloitte. In 2021, the projected R&D return on investment (ROI) rose 7%. For comparison, the ROI level in 2010 was 2.7%. Forecast peak sales per asset hit $521 million, up more than 23% over the $422 million…